Simultaneous laparoscopic nephroureterectomy and cystectomy: a preliminary report
Rodrigo Barros1, Rodrigo Frota, Robert J Stein
1Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Summary
Simultaneous laparoscopic radical nephroureterectomy and cystectomy is a feasible surgical approach for patients with upper tract tumors and bladder cancer. This minimally invasive technique demonstrated good outcomes in a small patient cohort.
Area of Science:
- Urologic Oncology
- Minimally Invasive Surgery
- Laparoscopic Surgery
Background:
- Muscle-invasive bladder cancer with upper urinary tract tumors often requires radical cystectomy and nephroureterectomy.
- End-stage renal disease or non-functioning kidneys also necessitate bladder and kidney removal.
- Simultaneous surgical removal presents unique clinical challenges and considerations.
Purpose of the Study:
- To report the institutional laparoscopic experience with simultaneous radical cystectomy and nephroureterectomy.
- To evaluate the technical feasibility and early outcomes of this combined laparoscopic procedure.
Main Methods:
- Retrospective analysis of 8 patients undergoing simultaneous laparoscopic radical nephroureterectomy (LNU) and radical cystectomy (LRC) between 2000 and 2007.
- Data collected included demographics, pathology, surgical technique, operative time, blood loss, hospital stay, and complications.
- Follow-up data were analyzed for overall and cancer-specific survival rates.
Main Results:
- The laparoscopic approach was technically successful in all 8 patients without open conversion.
- Median operative time was 9 hours, with a median estimated blood loss of 755 mL and hospital stay of 7.5 days.
- Low complication rates (1 major, 2 minor) were observed, with 87.5% cancer-specific survival at median follow-up of 9 months.
Conclusions:
- Simultaneous laparoscopic nephroureterectomy and cystectomy is technically feasible.
- The procedure demonstrated acceptable short-term outcomes and oncologic control in this initial series.
- Further studies with larger patient numbers and longer follow-up are needed to validate these findings.
